Symbols / ICU $4.58 +6.26% SeaStar Medical Holding Corporation

Healthcare • Biotechnology • United States • NCM
ICU Chart
About

SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 18.29M
Enterprise Value 5.76M Income -12.15M Sales 1.23M
Book/sh 2.71 Cash/sh 3.00 Dividend Yield —
Payout 0.00% Employees 17 IPO —
P/E — Forward P/E -1.78 PEG —
P/S 14.82 P/B 1.69 P/C —
EV/EBITDA — EV/Sales 4.67 Quick Ratio 3.27
Current Ratio 3.63 Debt/Eq 5.04 LT Debt/Eq —
EPS (ttm) -5.86 EPS next Y -2.57 EPS Growth —
Revenue Growth 5.27% Earnings 2026-03-25 16:00 ROA -80.88%
ROE -295.15% ROIC — Gross Margin 95.70%
Oper. Margin -7.18% Profit Margin 0.00% Shs Outstand 3.99M
Shs Float 3.95M Short Float 4.45% Short Ratio 3.20
Short Interest — 52W High 14.70 52W Low 2.07
Beta -1.19 Avg Volume 152.26K Volume 346.34K
Target Price $9.00 Recom Buy Prev Close $4.31
Price $4.58 Change 6.26%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.00
Mean price target
2. Current target
$4.58
Latest analyst target
3. DCF / Fair value
$-42.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.58
Low
$6.00
High
$12.00
Mean
$9.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-04-20 init Maxim Group — → Buy $5
News
RSS: Latest ICU news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-19 BAIRD JENNIFER A Director — 4,200 $0.24 $987
2025-12-09 MESSINGER MICHAEL Chief Financial Officer — 14,500 $0.35 $5,098
2025-08-27 VAN HEEL KENNETH J. Director — 35,000 $0.86 $30,812
2025-08-22 CHUNG KEVIN Officer — 10,000 $0.80 $8,000
2025-07-10 VAN HEEL KENNETH J. Director — 4,000 — —
2025-07-10 NEUMAN JOHN Director — 4,000 — —
2025-07-10 BAIRD JENNIFER A Director — 4,000 — —
2025-07-10 VINCENT BERNADETTE N Director — 4,000 — —
2025-07-01 SCHLORFF ERIC Chief Executive Officer — 21,667 — —
2025-07-01 CHUNG KEVIN Officer — 5,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.23
+814.07%
0.14
0.00
0.00
Operating Revenue
1.23
+814.07%
0.14
0.00
0.00
Cost Of Revenue
0.05
0.00
0.00
—
Reconciled Cost Of Revenue
0.05
0.00
0.00
—
Gross Profit
1.18
+774.81%
0.14
0.00
—
Operating Expense
13.36
-25.71%
17.98
+26.51%
14.21
+22.41%
11.61
Research And Development
7.52
-17.43%
9.11
+52.44%
5.97
+138.63%
2.50
Selling General And Administration
5.84
-34.20%
8.87
+7.71%
8.24
+19.10%
6.92
General And Administrative Expense
5.84
-34.20%
8.87
+7.71%
8.24
+19.10%
6.92
Other Gand A
5.84
-34.20%
8.87
+7.71%
8.24
+19.10%
6.92
Other Operating Expenses
—
—
—
2.19
Total Expenses
13.41
-25.41%
17.98
+26.51%
14.21
+22.41%
11.61
Operating Income
-12.18
+31.76%
-17.84
-25.56%
-14.21
-22.41%
-11.61
Total Operating Income As Reported
-12.18
+31.76%
-17.84
-25.56%
-14.21
-22.41%
-11.61
EBITDA
-12.12
+50.71%
-24.58
+2.26%
-25.15
-117.59%
-11.56
Normalized EBITDA
-12.15
+49.14%
-23.89
-22.88%
-19.44
-67.45%
-11.61
EBIT
-12.12
+50.71%
-24.58
+2.26%
-25.15
-117.59%
-11.56
Total Unusual Items
0.03
+104.59%
-0.70
+87.80%
-5.71
-11524.00%
0.05
Total Unusual Items Excluding Goodwill
0.03
+104.59%
-0.70
+87.80%
-5.71
-11524.00%
0.05
Special Income Charges
—
0.00
+100.00%
-4.95
0.00
Other Special Charges
—
—
4.95
—
Net Income
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Pretax Income
-12.15
+51.07%
-24.83
+5.36%
-26.23
-115.21%
-12.19
Net Non Operating Interest Income Expense
-0.00
+97.20%
-0.14
+86.77%
-1.08
-71.59%
-0.63
Interest Expense Non Operating
0.03
-87.30%
0.24
-77.43%
1.08
+71.59%
0.63
Net Interest Income
-0.00
+97.20%
-0.14
+86.77%
-1.08
-71.59%
-0.63
Interest Expense
0.03
-87.30%
0.24
-77.43%
1.08
+71.59%
0.63
Interest Income Non Operating
0.33
+221.78%
0.10
0.00
—
Interest Income
0.33
+221.78%
0.10
0.00
—
Other Income Expense
0.03
+100.47%
-6.84
+37.46%
-10.94
-21982.00%
0.05
Other Non Operating Income Expenses
—
-6.14
-17.52%
-5.23
—
Gain On Sale Of Security
0.03
+104.59%
-0.70
+8.65%
-0.76
-1626.00%
0.05
Tax Provision
0.00
+0.00%
0.00
0.00
-100.00%
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.01
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Net Income From Continuing Operation Net Minority Interest
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Net Income From Continuing And Discontinued Operation
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Net Income Continuous Operations
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Normalized Income
-12.18
+49.55%
-24.13
-17.61%
-20.52
-67.65%
-12.24
Net Income Common Stockholders
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Diluted EPS
—
-66.33
+78.08%
-302.60
+56.77%
-700.00
Basic EPS
—
-66.33
+78.08%
-302.60
+56.77%
-700.00
Basic Average Shares
—
0.37
+331.88%
0.09
+163.91%
0.03
Diluted Average Shares
—
0.37
+331.88%
0.09
+163.91%
0.03
Diluted NI Availto Com Stockholders
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Gain On Sale Of PPE
—
—
—
—
Total Other Finance Cost
0.30
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
14.16
+203.95%
4.66
+32.59%
3.51
+15.64%
3.04
Current Assets
13.58
+260.59%
3.77
+63.17%
2.31
+51.94%
1.52
Cash Cash Equivalents And Short Term Investments
11.98
+558.60%
1.82
+933.52%
0.18
+274.47%
0.05
Cash And Cash Equivalents
11.98
+558.60%
1.82
+933.52%
0.18
+274.47%
0.05
Cash Financial
11.98
+558.60%
1.82
+933.52%
0.18
+274.47%
0.05
Receivables
0.24
+111.61%
0.11
0.00
-100.00%
0.01
Accounts Receivable
0.24
+111.61%
0.11
0.00
—
Gross Accounts Receivable
0.24
+114.29%
0.11
—
—
Allowance For Doubtful Accounts Receivable
-0.00
0.00
—
—
Other Receivables
—
—
—
0.01
Inventory
0.07
0.00
—
—
Prepaid Assets
1.30
-29.32%
1.83
-13.93%
2.13
+46.03%
1.46
Total Non Current Assets
0.58
-35.20%
0.89
-25.98%
1.21
-20.67%
1.52
Other Non Current Assets
0.58
-35.20%
0.89
-25.98%
1.21
-20.67%
1.52
Total Liabilities Net Minority Interest
3.74
-45.30%
6.84
-60.65%
17.38
-26.96%
23.80
Current Liabilities
3.74
-45.30%
6.84
-47.56%
13.05
-19.21%
16.15
Payables And Accrued Expenses
3.22
-48.41%
6.23
+5.75%
5.89
+41.30%
4.17
Payables
0.95
-68.88%
3.05
-30.33%
4.37
+126.88%
1.93
Accounts Payable
0.95
-68.88%
3.05
-30.33%
4.37
+126.88%
1.93
Current Accrued Expenses
2.27
-28.86%
3.19
+109.32%
1.52
-32.16%
2.25
Current Debt And Capital Lease Obligation
0.53
-8.54%
0.57
-87.90%
4.74
+302.72%
1.18
Current Debt
0.53
-8.54%
0.57
-87.90%
4.74
+302.72%
1.18
Other Current Borrowings
0.53
-8.54%
0.57
-87.90%
4.74
+302.72%
1.18
Current Deferred Liabilities
—
0.00
-100.00%
0.10
—
Current Deferred Revenue
—
0.00
-100.00%
0.10
—
Other Current Liabilities
0.00
-96.97%
0.03
-98.57%
2.31
-78.63%
10.80
Total Non Current Liabilities Net Minority Interest
0.00
0.00
-100.00%
4.34
-43.32%
7.65
Long Term Debt And Capital Lease Obligation
—
—
4.34
-43.32%
7.65
Long Term Debt
—
—
4.34
-43.32%
7.65
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
10.42
+577.14%
-2.18
+84.26%
-13.87
+33.20%
-20.76
Common Stock Equity
10.42
+577.14%
-2.18
+84.26%
-13.87
+33.20%
-20.76
Capital Stock
0.00
+100.00%
0.00
+100.00%
0.00
+0.00%
0.00
Common Stock
0.00
+100.00%
0.00
+100.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
3.84
+543.21%
0.60
+213.83%
0.19
+274.94%
0.05
Ordinary Shares Number
3.84
+543.21%
0.60
+213.83%
0.19
+274.94%
0.05
Additional Paid In Capital
162.13
+18.01%
137.38
+36.20%
100.86
+48.90%
67.74
Retained Earnings
-151.71
-8.71%
-139.56
-21.64%
-114.73
-29.64%
-88.50
Total Equity Gross Minority Interest
10.42
+577.14%
-2.18
+84.26%
-13.87
+33.20%
-20.76
Total Capitalization
10.42
+577.14%
-2.18
+77.10%
-9.53
+27.28%
-13.11
Working Capital
9.84
+419.93%
-3.08
+71.36%
-10.74
+26.60%
-14.63
Invested Capital
10.94
+779.99%
-1.61
+66.40%
-4.79
+59.86%
-11.93
Total Debt
0.53
-8.54%
0.57
-93.68%
9.08
+2.84%
8.83
Net Debt
—
—
8.90
+1.39%
8.78
Net Tangible Assets
10.42
+577.14%
-2.18
+84.26%
-13.87
+33.20%
-20.76
Tangible Book Value
10.42
+577.14%
-2.18
+84.26%
-13.87
+33.20%
-20.76
Current Notes Payable
—
—
—
1.18
Derivative Product Liabilities
—
—
—
0.00
Financial Assets
—
—
—
1.73
Interest Payable
—
—
0.02
-83.04%
0.11
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.60
+15.04%
-16.01
-55.63%
-10.29
-31.96%
-7.79
Cash Flow From Continuing Operating Activities
-13.60
+15.04%
-16.01
-55.63%
-10.29
-31.96%
-7.79
Net Income From Continuing Operations
-12.15
+51.07%
-24.83
+5.34%
-26.23
-115.19%
-12.19
Other Non Cash Items
0.32
+209.80%
0.10
+112.50%
0.05
-91.77%
0.58
Stock Based Compensation
0.62
-29.65%
0.89
-54.04%
1.93
+47.22%
1.31
Operating Gains Losses
-0.03
-104.59%
0.70
-87.80%
5.71
+11524.00%
-0.05
Gain Loss On Investment Securities
-0.03
-104.59%
0.70
-8.65%
0.76
+1626.00%
-0.05
Unrealized Gain Loss On Investment Securities
0.00
-100.00%
6.14
+14.22%
5.38
0.00
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
-2.36
-337.60%
0.99
-65.52%
2.88
+12.74%
2.55
Change In Receivables
-0.12
-11.61%
-0.11
-1033.33%
0.01
+200.00%
0.00
Changes In Account Receivables
-0.12
-11.61%
-0.11
0.00
—
Change In Inventory
-0.07
0.00
—
0.00
Change In Prepaid Assets
0.54
+81.14%
0.30
+406.19%
-0.10
+90.96%
-1.07
Change In Payables And Accrued Expense
-3.02
-608.08%
0.59
-79.95%
2.96
-18.20%
3.62
Change In Accrued Expense
-0.92
-149.07%
1.88
+262.67%
0.52
-75.06%
2.07
Change In Payable
-2.10
-63.78%
-1.28
-152.39%
2.44
+57.95%
1.55
Change In Account Payable
-2.10
-63.78%
-1.28
-152.39%
2.44
+57.95%
1.55
Change In Other Current Assets
0.31
+0.32%
0.31
0.00
—
Change In Other Current Liabilities
0.00
+100.00%
-0.10
0.00
—
Financing Cash Flow
23.76
+34.62%
17.65
+69.48%
10.41
+42.05%
7.33
Cash Flow From Continuing Financing Activities
23.76
+34.62%
17.65
+69.48%
10.41
+42.05%
7.33
Net Issuance Payments Of Debt
-0.07
+98.48%
-4.41
-224.93%
3.53
+1.41%
3.48
Issuance Of Debt
0.77
-54.67%
1.69
-80.77%
8.80
+147.26%
3.56
Repayment Of Debt
-0.83
+86.33%
-6.10
-15.79%
-5.27
-6656.41%
-0.08
Long Term Debt Issuance
0.77
-54.67%
1.69
-80.77%
8.80
+147.26%
3.56
Long Term Debt Payments
-0.83
+86.33%
-6.10
-15.79%
-5.27
-6656.41%
-0.08
Net Long Term Debt Issuance
-0.07
+98.48%
-4.41
-224.93%
3.53
+1.41%
3.48
Net Common Stock Issuance
16.13
-7.54%
17.44
+163.78%
6.61
-33.89%
10.00
Proceeds From Stock Option Exercised
7.70
+66.72%
4.62
+498.32%
0.77
+115.63%
-4.94
Net Other Financing Charges
—
—
-0.50
+58.71%
-1.21
Changes In Cash
10.16
+518.44%
1.64
+1173.64%
0.13
+127.86%
-0.46
Beginning Cash Position
1.82
+933.52%
0.18
+274.47%
0.05
-90.78%
0.51
End Cash Position
11.98
+558.60%
1.82
+933.52%
0.18
+274.47%
0.05
Free Cash Flow
-13.60
+15.04%
-16.01
-55.63%
-10.29
-31.96%
-7.79
Interest Paid Supplemental Data
0.00
-100.00%
0.55
-50.89%
1.13
+18666.67%
0.01
Income Tax Paid Supplemental Data
0.00
+0.00%
0.00
0.00
-100.00%
0.00
Common Stock Issuance
16.13
-7.54%
17.44
+163.78%
6.61
-33.89%
10.00
Issuance Of Capital Stock
16.13
-7.54%
17.44
+163.78%
6.61
-33.89%
10.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category